Clinical characteristics, anti-hyperglycaemic treatment pattern and target attainment of type 2 diabetes mellitus patients in older population with or without albuminuria in China: A nationwide cross-sectional study

First published: 22/02/2017

Last updated: 22/02/2017

Study   Planned

Administrative details

PURI

https://redirect.ema.europa.eu/resource/17923

EU PAS number

EUPAS17922

Study ID

17923

DARWIN EU® study

No

Study countries

☐ China

Study description

Clinical characteristics, anti-hyperglycaemic treatment pattern and target attainment of type 2 diabetes mellitus patients in older population with or without albuminuria in China: A nationwide cross-sectional study

---

Study status

Planned

Research institutions and networks

Institutions

Boehringer Ingelheim

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Mei Mao

Study contact

mei.mao@boehringer-ingelheim.com

Primary lead investigator

Mei Mao

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 16/11/2015

Actual: 16/11/2015

Study start date

Planned: 15/03/2017

Data analysis start date

Planned: 15/03/2017

Date of final study report

Planned: 04/09/2018

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Boehringer Ingelheim

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Main study objective:

to assess the level of blood glucose, measured by the proportion of patients attaining the blood glucose control target defined as HbA1c<7%.

Study Design

Non-interventional study design

Cross-sectional

Study drug and medical condition

Medical condition to be studied

Type 2 diabetes mellitus

Population studied

Age groups

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

1500

Study design details

Outcomes

The primary outcome is the proportion of patients attaining blood glucose control target defined as HbA1c<7%, according to 2015 American Diabetes Association (ADA) and 2013 Chinese Diabetes Society (CDS) guidelines. Renal function level of patientsTreatment regimens for T2DM that patient are currently takingProportion of macro vascular and micro vascular diabetic complicationsProportion of Hypoglycaemic occurrenceProportion of Hypoglycaemia leading to therapy changeProportion of Anti-hypertension therapy usageProportion of Lipid Lowering therapy usageProportion of Anti-Platelet therapy usage

Data analysis plan

Descriptive statistics such as mean, standard deviation, median and range (minimum, maximum) will be used to summarize continuous variables. Counts and percentages will be used to summarize categorical variables. The chi-square test will be used to compare the categorical data between groups and the t-test will be used to compare the continuous variables that are normally distributed. For variables that are not normally distributed, non-parametric tests will be used.To identify the factors associated with overall blood glucose control, a stepwise logistic regression will be used.Missing data will not be imputed. Statistical significance will be assessed at a two-sided 0.05 level in an explorative way. All analysis will be conducted using SAS software.

Data management

Data sources

Data sources (types)

Disease registry

Other

Data sources (types), other

Exposure registry

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No